Last reviewed · How we verify
saline infusion
Saline infusion replaces or maintains fluid and electrolyte balance by delivering a sterile sodium chloride solution intravenously.
Saline infusion replaces or maintains fluid and electrolyte balance by delivering a sterile sodium chloride solution intravenously. Used for Fluid and electrolyte replacement in dehydration, Perioperative fluid management, Maintenance of vascular access and hemodynamic support.
At a glance
| Generic name | saline infusion |
|---|---|
| Also known as | saline, Saline, Normal saline solution, 0.9% sodium chloride solution, normal saline infusion |
| Sponsor | University Hospital, Linkoeping |
| Drug class | Electrolyte solution / Fluid replacement |
| Modality | Small molecule |
| Therapeutic area | Supportive Care / General Medicine |
| Phase | FDA-approved |
Mechanism of action
Saline infusion is a basic supportive therapy that provides isotonic fluid containing 0.9% sodium chloride to restore intravascular volume, maintain hydration, and preserve electrolyte homeostasis. It is used across multiple clinical settings to prevent or treat dehydration, support hemodynamic stability, and serve as a vehicle for other medications.
Approved indications
- Fluid and electrolyte replacement in dehydration
- Perioperative fluid management
- Maintenance of vascular access and hemodynamic support
Common side effects
- Hyperchloremic acidosis
- Fluid overload / pulmonary edema
- Hypokalemia
- Phlebitis at infusion site
Key clinical trials
- Effect of Lidocaine Infusion Versus Dexmedemidine Infusion on the Neurocognitive Function of Elderly Patients Undergoing Endoscopic Retrograde Cholangiopancreatography(ERCP): a Randomized, Controlled Trial. (NA)
- Pulse Glucocorticoid Therapy in Patients With ST-Segment Elevation Myocardial Infarction (PHASE2)
- Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies (PHASE1)
- MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM) (PHASE3)
- Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis (PHASE2)
- Water Deprivation Protocol (NA)
- Normal Saline Infusion After Intravenous Thrombolysis in Stroke (PHASE3)
- Management of Pain in Lumbar Arthrodesis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- saline infusion CI brief — competitive landscape report
- saline infusion updates RSS · CI watch RSS
- University Hospital, Linkoeping portfolio CI